Not currently recruiting at UCLA
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Summary
- Eligibility
- for people ages 18-130 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startestimated completion
- Principal Investigator
- by Herbert Eradat
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Herbert Eradat
HS Clinical Professor, Medicine. Authored (or co-authored) 21 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Acerta Pharma BV
- ID
- NCT03836261
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 780 study participants
- Last Updated